Creek Drive Management Group LLC cut its holdings in shares of CeriBell, Inc. (NASDAQ:CBLL – Free Report) by 40.6% in the third quarter, HoldingsChannel reports. The firm owned 178,750 shares of the company’s stock after selling 122,131 shares during the period. CeriBell accounts for about 1.2% of Creek Drive Management Group LLC’s holdings, making the stock its 18th biggest holding. Creek Drive Management Group LLC’s holdings in CeriBell were worth $4,360,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE acquired a new stake in shares of CeriBell in the second quarter valued at approximately $4,619,000. TimesSquare Capital Management LLC bought a new position in CeriBell in the 2nd quarter worth approximately $15,182,000. BlackRock Inc. acquired a new position in CeriBell during the 2nd quarter worth $37,657,000. Bank of New York Mellon Corp acquired a new position in CeriBell during the 2nd quarter worth $17,437,000. Finally, Deutsche Bank AG bought a new position in CeriBell in the 2nd quarter valued at $1,742,000.
Insider Buying and Selling
In other news, CEO Xingjuan Chao sold 39,540 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $24.61, for a total value of $973,079.40. Following the completion of the transaction, the chief executive officer owned 767,191 shares of the company’s stock, valued at $18,880,570.51. The trade was a 4.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP David Foehr sold 9,255 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $24.25, for a total transaction of $224,433.75. Following the completion of the sale, the vice president owned 34,144 shares of the company’s stock, valued at approximately $827,992. This represents a 21.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 151,781 shares of company stock worth $3,841,141 over the last ninety days. Insiders own 17.70% of the company’s stock.
CeriBell Stock Down 1.3%
Shares of NASDAQ CBLL opened at $25.63 on Thursday. The stock has a market cap of $995.21 million, a P/E ratio of -13.21 and a beta of 0.86. The firm has a 50 day moving average price of $25.61 and a 200 day moving average price of $21.12. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.79 and a current ratio of 8.18. CeriBell, Inc. has a 52-week low of $13.20 and a 52-week high of $28.89.
CeriBell (NASDAQ:CBLL – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). The firm had revenue of $29.34 million during the quarter, compared to the consensus estimate of $29.18 million. CeriBell had a negative net margin of 67.96% and a negative return on equity of 52.59%. Analysts expect that CeriBell, Inc. will post -2.05 EPS for the current year.
Analyst Ratings Changes
Several equities research analysts have recently commented on the company. Raymond James Financial reissued a “strong-buy” rating and issued a $29.00 target price on shares of CeriBell in a research note on Thursday, September 3rd. BTIG Research restated a “buy” rating on shares of CeriBell in a research report on Wednesday, November 4th. TD Cowen upped their price target on CeriBell from $29.00 to $33.00 and gave the company a “buy” rating in a research note on Friday, October 2nd. Canaccord Genuity Group raised their price target on CeriBell from $26.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, November 4th. Finally, Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 16th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.25.
Get Our Latest Stock Report on CeriBell
CeriBell Profile
Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.
See Also
- Five stocks we like better than CeriBell
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding CBLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CeriBell, Inc. (NASDAQ:CBLL – Free Report).
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
